Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aprea Therapeutics Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently faces 2 pending office actions. These matters are distributed across 2 distinct examiners and 2 distinct art units, indicating a diversified review process even with a small number of filings in the pharmaceutical sector.
The busiest examiner for the portfolio is SHIAO, REI TSANG, who is currently handling 1 busiest examiner pending action. This means the 2 pending office actions are split equally between the busiest examiner and one other official. For practitioners, this distribution across 2 distinct art units suggests that the biotechnology and pharmaceutical claims are being evaluated under different specialized criteria within the office. This lack of concentration requires a flexible prosecution strategy that can address the varying requirements of two different examiners and two separate technical units simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565598 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 53d |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18855713 | ATR INHIBITORS | SHIAO, REI TSANG | 1691 | §103 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18565598 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103§112DP | Non-Final OA | 53d | Pending | Nov 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAprea Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Rei Tsang Shiao has the most, with 1 of Aprea Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
